In 2023, C. Russell Trenary III earned $610.90K in total compensation at Outlook Therapeutics, Inc., primarily from $600.00K salary. Most recently acquired 19,925 shares in Jun 2022. Currently holds stock worth $112.60K. Led Outlook Therapeutics, Inc. as CEO for 3 years.
Compensation History
Annual executive compensation data for C. Russell Trenary III, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$610.90K
Salary
$600.00K
Bonus
$0.00
Other
$10.90K
Salary
$600.00KBoard Justification
The compensation philosophy is designed to attract, reward, and retain executives necessary for the company's growth and profitability, aligning with shareholder interests.
Bonus
$0.00Board Justification
No bonus was awarded for the year 2023.
Other Compensation
$10.90KBoard Justification
Includes payment of term life insurance premiums and 401(k) matching contributions.
Restricted Stock
Board Justification
No stock was vested in 2023 as the only options granted were not vested yet.
Performance Metrics
The performance metrics for determining compensation include the achievement of specific performance milestones related to stock options.
C. Russell Trenary III
Ex-CEO of Outlook Therapeutics, Inc.
Sector of Economy
Healthcare
CEO of Outlook Therapeutics, Inc. for
3 years 4 months (Jul 2021 - Dec 2024)
Previous Experience
President and CEO of InnFocus, Inc. until its acquisition by Santen Pharmaceutical.
Holdings
Track C. Russell Trenary III's stock holdings and portfolio value over time.
Insider Trading
C. Russell Trenary III's recent stock transactions, purchases, and sales filed with the SEC.
$21.12K
OTLK at $1.06/share
Jun 21, 2022
Purchase
$34.75K
OTLK at $1.39/share
Dec 6, 2021
Purchase
$14.00K
OTLK at $1.40/share
Dec 2, 2021
Purchase
Rivals
Compare C. Russell Trenary III with competitor CEOs and industry peers.